We’re not immune to publicity: Keep up with our story below

MiroBio is committed to scientific and industry engagement in pursuit of our vision for a new approach to autoimmune disease therapies. Below you can review our news and other updates for our network.

Press Release

March 8, 2022

MiroBio Continues Expansion of Executive Leadership Team with Key Appointments to Advance Development of Checkpoint Agonist Antibodies for Autoimmune Disease

Sanjay Keswani, MBBS, FRCP to join company as Chief Medical Officer bringing extensive experience in drug development and life sciences leadership Lynne Murray, Ph.D., MBA appointed as Chief Scientific Officer…

September 21, 2021

Dr. Carolin Barth Joins MiroBio as CEO to Lead Precision Immunology Company Focused on Checkpoint Agonist Antibodies

Former Novartis executive to lead emerging biotech with a novel precision approach to autoimmune disease, supported by recent senior appointments MiroBio is exclusively focused on checkpoint agonists produced by its…

October 7, 2019

MiroBio launches with £27m ($34m) Series A from leading life sciences investors

Oxford start-up developing novel therapeutics based on deep expertise in immune cell regulation Oxford, UK, October 7 2019 – MiroBio, a novel therapeutics company based on insights into the regulation…

Your browser is out-of-date!

Update your browser to view this website correctly. Outdated Browser